Search research articles
Contact Us
Filters
Showing results (81-90 of 107) with videos related to
Page
of 11
Sort By:
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B
Marte Holmberg, Annika Niehrs, Olav Dalgard, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Qinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Journal of Hepatology
|
October 30, 2017
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
Hannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine
|
August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
Jason Grebely, Gregory J Dore, Frederick L Altice, et al.
Page
of 11
Search research articles
Search
Showing results (81-90 of 107) with videos related to
Sort By:
Page
of 11
JHEP Reports : Innovation in Hepatology
|
May 1, 2026
Hepatic flares, their immune signatures, and ALT variability after nucleos(t)ide analogue cessation in HBeAg-negative hepatitis B
Marte Holmberg, Annika Niehrs, Olav Dalgard, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
January 16, 2023
Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs
Qinglu Cheng, Evan B Cunningham, Sophy Shih, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 14, 2019
Patterns of Drug and Alcohol Use and Injection Equipment Sharing Among People With Recent Injecting Drug Use or Receiving Opioid Agonist Treatment During and Following Hepatitis C Virus Treatment With Direct-acting Antiviral Therapies: An International Study
Andreea A Artenie, Evan B Cunningham, Gregory J Dore, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
November 3, 2019
Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
The International Journal on Drug Policy
|
June 19, 2017
Efficacy of response-guided directly observed pegylated interferon and self-administered ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: The ACTIVATE study
Jason Grebely, Olav Dalgard, Evan B Cunningham, et al.
Journal of Hepatology
|
October 30, 2017
Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe
Hannah Fraser, Natasha K Martin, Henrikki Brummer-Korvenkontio, et al.
BMC Infectious Diseases
|
June 15, 2017
Adherence to response-guided pegylated interferon and ribavirin for people who inject drugs with hepatitis C virus genotype 2/3 infection: the ACTIVATE study
Evan B Cunningham, Behzad Hajarizadeh, Olav Dalgard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
March 14, 2020
Reinfection Following Successful Direct-acting Antiviral Therapy for Hepatitis C Virus Infection Among People Who Inject Drugs
Evan B Cunningham, Behzad Hajarizadeh, Janaki Amin, et al.
Journal of Hepatology
|
September 1, 2015
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Gregory J Dore, Brian Conway, Yan Luo, et al.
Annals of Internal Medicine
|
August 8, 2022
Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy : A Cohort Study
Jason Grebely, Gregory J Dore, Frederick L Altice, et al.
Page
of 11